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Clinical physica b s t r a c t
As the COVID-19 spread continues to challenge the societal and professional norms, radiotherapy around
the globe is pushed into an unprecedented transformation. We will discuss how clinical physics has
transformed to ascertain safety and quality standards across four facilities around the world through
diversity of action, innovation, and scientific flexibility.
Crown Copyright  2020 Published by Elsevier B.V. All rights reserved. Radiotherapy and Oncology
148 (2020) 274–278The COVID-19 pandemic, caused by the SARS-CoV-2 virus, has
led to over 6.5 million confirmed infections and 380,000 deaths
globally [1]. As of now, any specific treatment or vaccine is lagging
behind the rapid spread of this contagious illness. The aerosol and
fomite transmission of the agent is likely and the experimental
studies have demonstrated that the SARS-CoV-2 can survive sev-
eral hours in air (and up to several days on certain surfaces) [2];
hence the natural course of action against the disease is to avoid
exposure from the respiratory secretions of an infected individual
[3]. In order to slow down spread of the disease, WHO and various
national health agencies recommend physical distancing of 2 m
between individuals which is being implemented as ‘‘social-dis
tancing” in various parts of the world. This very benign advice
has caused mayhem in all walks of modern life. From Asia to the
Americas, almost everywhere, states, and jurisdictions haveimposed restrictions on non-essential contact by issuing stay-at-
home, or lock-down orders. In hospitals, including radiation oncol-
ogy facilities, prevention and control measures are in place to
ensure safety of the cancer patients, health professionals and care-
givers, and to manage treatment of suspected or COVID-19 positive
cancer patients. Clinical workflow and contingency measures from
several radiation therapy (RT) departments are now part of the
emerging literature [4–18]. Several individuals and organizations,
such as ASTRO and ESTRO, have published opinions, recommenda-
tions and guidelines on RT management of cancer patients, such as
for head and neck [19,20], lung [21], breast [22], gastrointestinal
[23], gynecological [24], rectum [25], prostate [26], and emergency
palliative care [27].
Medical physicists across the world provide supporting roles in
RT including administration, direct clinical services, equipment
performance evaluation, quality assurance, safety, informatics,
education and training, research, and service development
[28,29]. In order to execute these tasks safely and efficiently, they
have to operate in teams, supervise staff, provide consultation and
in some activities face-to-face patient interactions. Although the
philosophy behind clinical physics operations is similar, various
tasks can be accomplished in different order or under different
constraints arising from organizational culture and operational
environment. Under various constraints of social distancing, one
important question commonly asked is: ‘‘how much quality assur-
ance (QA) is enough?” Since the COVID-19 outbreak, there has
been a sudden transformation of clinical physics tasks with no
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ment how the practice patterns have changed in different parts
of the world [18]. The majority of emerging literature lacks details
of how various clinical physics workflow and operations have
adapted to the new realities. Therefore, in this work, we will pro-
vide a snapshot of common radiotherapy physics workflow across
a geographical sample of clinics in North America and Europe with
the aim that it will provide supporting data to develop some con-
sensus through diversity of approaches. These clinics operate
under various fiscal models, human resources, societal norms,
and other healthcare constraints.Fig. 1. General radiotherapy process and clinical physics roles. The process
elements are adaptable for stereotactic body radiotherapy (SBRT), high dose rate
(HDR), low dose rate (LDR) brachytherapy, stereotactic radiosurgery, (SRS) and 3D
conformal radiotherapy (3D-CRT).Methods
Four variable sized, geographically distributed, cancer clinics A
(St. Louis, MO, USA), B (Victoria, BC, Canada), C (Exeter, Devon, UK)
and D (Campobasso, Italy) were included in this study. Except for
A, all other clinics operate under public healthcare model. Clinic
A represent a large academic institution employing 37 full time
equivalent (FTE) physicists, with external beam radiation treat-
ments, (EBRT) on 13 TruebeamTM (Varian Medical Systems, Palo
Alto, CA) linacs integrated with an Eclipse and Aria 15.6 hosted
in a cloud network. The clinic also performs MRI-guided radiother-
apy (MRgRT) adaptive radiotherapy, proton therapy, several forms
of brachytherapy, and various radiopharmaceutical treatments.
Clinic B is a tertiary healthcare facility employing nine physicists,
offering high dose rate (HDR) gynecology brachytherapy, low dose
rate prostate seed implants, radiopharmaceutical treatments and
external beam treatments on six TruebeamTM linacs integrated with
an EclipseTM and an Aria 15.6 platform hosted provincially. Clinic C
is a National Health Service (NHS) cancer care facility having nine
physicists, offering HDR prostate and gynecology brachytherapy,
and EBRT on three Varian linacs integrated into an Aria 15.6 plat-
form hosted locally. Clinic D is a public cancer care facility with
three physicists, offering EBRT on two Versa HD ElektaTM linacs
(Elekta Oncology Systems, Crawley, UK) integrated into a Mosaiq
2.64 platform hosted locally.
The main goal of all four facilities in responding to the current
situation was to sustain safe and efficient operability of radiother-
apy under the constraints of social distancing and local guidelines.
All radiotherapy treatments involve general work flow as follows
(Fig. 1).
A summary of clinical physics practice patterns for the four
radiotherapy facilities both prior to and during the outbreak is pro-
vided in Table 1, where tasks are allocated to those able to be car-
ried out remotely or those needing the physical presence in the
clinic of a physicist. The study was restricted to the most common
tasks performed by at least three of the participating institutions,
other specialized tasks for total body irradiation (TBI), MRgRT, pro-
ton therapy etc., were not included in the comparison.General response to disruption
In order to avoid possible spread of the contagion, the physics
staffing was split into two teams: on-site and remote; their roles
would be exchanged on a weekly basis or between early and late
shift. Each teammember was selected based on their ability to per-
form a variety of procedures. The site team practiced physical dis-
tancing, and used appropriate personnel protective equipment
(PPE) when called to a procedure room.
In response to the pandemic, the medical physics tasks were
prioritized into essential tasks and non-urgent tasks that can toler-
ate delays and postponement (e.g., annual QA). Patient-specific QA,
equipment QA, and commissioning of equipment and safety checks
following relevant maintenance interventions were prioritized.The QA activities were moved to after-hours or weekends
where possible such as therapy equipment calibration, machine
QA and testing. Followed by the QA measurements, appropriate
disinfecting protocols were adopted to avoid possible contamina-
tion of the treatment equipment. In case of clinic D, patient-
specific QAs were performed early in the morning, prior to the start
of treatments.
The radiotherapy planning and management systems were set
up for remote working; in two institutions the information tech-
nology (IT) infrastructure was cloud-based, while in others, plan-
ning desktops and other computers were accessed through a
remote desktop application.
All communication between both teams and other RT staff were
accomplished through voice/video conferencing software through
Microsoft Teams (Microsoft, Redmond, WA) or Zoom (Zoom Video
Communications Inc., San Jose, CA). In all cases, it was ensured that
the software and hardware were compliant to country-specific reg-
ulations regarding patient privacy and data security by checking
with the providers.
Using either cloud-hosted treatment planning and management
system or remote access software, all four clinics could perform the
bulk of the plan quality checks, image registration, 3D-CRT, IMRT
and VMAT plan reviews, special techniques SRS, SBRT, etc. and
even HDR planning and reviews without compromising quality.
At each facility, interactions with other team members such as
radiotherapy technologists (RTTs), treatment planning dosime-
trists, and radiation oncologists, was achieved via virtual meetings
and shared screens.
Some tasks required on-site attendance by the physicist such as
patient setup and IGRT checks for SRS, SBRT, etc. on the first day of
treatment. All institutions required physical presence of a special-
ized physicist during the HDR brachytherapy delivery due to state
regulations.
Initially, following the guidelines for RT, a surge in number of
hypofractionated treatments across all four facilities happened,
which increased the clinical workload for about one week due to
re-planning of some patients undergoing treatment. However, this
may be mitigated by the smaller overall number of fractions
needed over a period of time.
Contingency plans were developed for possible radiotherapy of
COVID-19 infected cancer patients if required. This involved either
Table 1
Summary of practice patterns for common radiotherapy tasks performed by the clinical physicists prior to and during the COVID-19 outbreak. * represents physics consults – only















initial plan review, final
plan review; MU calc;
delivery QA
4D CT & motion management*,
fusion review, plan review, first
fraction patient setup, plan
delivery QA
CT & MR, motion management &
simulation, planning, plan review,
delivery QA & collision check; patient
setup and treatment delivery**




QA, delivery, and post
implant
During disruption All remote All remotely except,
patient-specific
delivery QA
All remotely except first
fraction patient setup and
patient specific delivery QA
All remotely except for simulation and
delivery**




delivery in person; rest
are done remotely
For IMRT and VMAT QA, clinic B uses an in-house Monte Carlo-based independent dose calculation software or occasional portal dosimetry measurements. Clinic B continued
to perform on-site initial modulated plan consultation and for single fraction treatments. Clinic C does not perform single fraction SRS treatments. Clinic D physics staff also
does treatment planning for modulated and hypofractionated treatments. Single fraction treatments are planned by physicists at D; Gammaknife SRS treatments at clinic A
are planned by a physicist. Clinic D does not perform any of the brachytherapy procedures listed above.
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the last time slot of the day. This is similar to existing protocols
already in place for radiotherapy of cancer patients with infectious
conditions. Following the treatment, the room would be thor-
oughly disinfected, and not used for the next 12 hours to ensure
no virus survived in the treatment space. In general, all new
patients with confirmed COVID-19 would have radiotherapy
delayed for several weeks. On-treatment patients identified with
COVID-19 + would be carefully evaluated according to their clinical
situation. If treatment cannot be stopped, patients must be treated
following the contingency plan described above. To date, none of
the participants have treated a known COVID-19 + patient with
radiotherapy.Institution specific details
Remote physics operations at institution A were initiated on
March 16. This involved all administration and treatment planning
dosimetrists to operate fully remotely, whereas physicists were
split into on-site and remote teams. Telecommuting has continued
unabated since then. The average fractions treated per day dropped
by about 20% since COVID-19 impacted operations began. The
physicians changed some plans to hypofractionated regimens,
which lead to surge in plan complexity and workload for about
one week. Due to a sufficient number of staff, the workload was
manageable. One week into the outbreak, two linacs were shut
down to have back-up therapists in order to overcome any short-
age of staff due to disease or other issues and also to use the rooms
for possible COVID19 + radiotherapy.
At institution B, one major advantage was using an in-house
Monte Carlo-based independent dose calculation for IMRT/VMAT
patient specific QA (if measurement is required it was performed
using EPID dosimetry afterhours) which further helped with
telecommuting.
At institution C, telecommuting operations started the week of
the March 23, which coincided with the beginning of general lock-
down measures in the UK, and then was expanded to administra-
tive and all treatment planning staff. Breast and prostate
treatments were converted to hypofractionation with a general
trend to hypofractionate other sites (sarcomas, rectum, etc.) where
possible. New starts for prostates were initially put on hold, later
they were resumed with various hypofractionated regimens
(36 Gy in 5 fx or 60 Gy in 20 fx). All prostate HDR and radioiodines
for thyroids were delayed indefinitely; only HDR treatments wereallowed for the gynecological sites. The reduction from 15 fractions
(for 40 Gy prescription) to 5 fractions (36 Gy prescription) for most
breast treatments was the major contributor to the overall reduc-
tion of the total patient workload.
The modified operations at institution D started on March 2,
2020, and the radiotherapy schedules rapidly moved towards
hypofractionation. Since Clinic D was the only regional hospital
providing radiotherapy, one of the major objectives was to main-
tain full access to radiation treatment even under emergency.
The number of daily treatment slots were not decreased. Instead,
by rearranging the work shifts and extending the treatment day
by extra three hours, spatial and temporal distancing between
patients and staff was ascertained. Since Italy was the first Euro-
pean country to witness a widespread outbreak of the coronavirus,
the government decreed increased restrictions within lockdown
areas/‘‘red zones”, which were later extended to the whole nation
on March 8, 2020. The Italian Association of Medical Physics
(AIFM) [30], following the suggestions of the European Federation
of Medical Physics Organizations (EFOMP) [31] issued directives
for the medical physics units operating in hospitals, with the aim
to keep treatment and diagnostic procedures as safe as possible.
Being a small physics group, to ensure social distancing, all on-
site physics personnel operated in separated areas and rooms,
while one physicist remotely worked from home (WFH) using
web-conferencing and on-line meeting tools.
General discussion and challenges
In the absence of professional guidelines on clinical physics
tasks during COVID-19, the goal of this short study was to under-
stand adaptation of medical physics operations in various environ-
ments, learn from mutual experience and help develop some
consensus on elasticity of physics tasks. The healthcare system in
the United States is mostly privately owned and operated, unlike
public or universal healthcare systems of Canada, United Kingdom
and Italy. This can lead to different approaches from higher man-
agement when it comes to crisis management. The major objective
of moving to a partially remote model was to provide unhindered
safe clinical support for radiotherapy of cancer patients, should
some of the physics staff become unavailable from infection or
other need to isolate. It may be noted that similar solutions were
adopted in reference [18], which presented specific discussion of
medical physics issues for COVID-19 operation of radiotherapy ser-
vices in an Australasian context.
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supply of PPE for the physics staff. After about one month of
remote operations, WFH has been stressful for the physics team
due to lack of interpersonal communication, face-to-face interac-
tions, bonding and inclusion, though modern communication
channels have provided some mitigation [32].
Due to restrictions on international travel, border closures, and
supply-chain issues, mobility of goods and RT supplies has become
uncertain. Radioactive 125I seeds treatments can suffer greatly due
to these disruptions resulting in potential cancelation of LDR
procedures.
There are some positive spinoffs of the COVID-19 work chal-
lenge. The institutional IT departments had to prioritize the imple-
mentation of WFH schemes, resistance to paperless initiatives
dropped, hypofractionated approaches were implemented for
breast and prostate radiotherapy as well as other sites with con-
current gains in time-efficiencies and possibly with equivalent or
better outcomes. During the COVID-19 constrained situation a
sense of closer working partnership between physicians, RTTs,
other technical staff, administrative support andmedical physicists
has been developing. However, the significant perturbations that
the COVID-19 response has caused in terms of delaying radiother-
apy, and scaling down of operations (~25%) will create a backlog of
patients that will challenge the effective and timely provision of
radiotherapy in the very near future. It is critical to prepare for this
reckoning, one can hope that the gains of workforce flexibility,
telecommuting schemes and hypofractionation-derived efficien-
cies can counterbalance an impending increased demand for radio-
therapy in post COVID-19 era. In addition, any postponed
equipment servicing or preventative maintenance will also have
to be rescheduled.
Another major challenge especially with smaller operations like
clinic D in the current study, was the smaller number of staff which
made it difficult to operate as two completely independent groups.
The staff reorganization was done to avoid any aggregation of per-
sonnel while guaranteeing the availability of staff and vital
resources for the continuity of care.
Though prioritizing of physics tasks in this work was done
heuristically and in order to react speedily to the developing crisis,
it may be more appropriate to deploy a systematic reliability engi-
neering approach such as an institution-specific failure modes and
effect analysis (FMEA) [33] to perform risk analysis for prioritizing
QA tasks. There is also an imminent need for a professional medical
physics task force to develop consensus on clinical physics tasks
under a pandemic or major catastrophe. Only a consensus can
address the amount of QA, preferred order of operations and other
relevant questions.
While we acknowledge that providing recommendations during
the spread of pandemic is challenging due to lack of data points
and the changing nature of the spread, sharing the commonalities
and contrasts of our experiences across these four cancer clinics
operating under different healthcare norms, along with those from
[18], could lead to consensus among the physics community.Conflicts of interest
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